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Background: Mycobacterium tuberculosis complex (MTC) is the causative agent of tuberculosis (TB). Globally,
increasing evidence shows that in M. tuberculosis, transmission varies from strain to strain and that different strains
exhibit a range of geographical and host specificities, pathogenicity, and drug susceptibility. Therefore rapid and
accurate differentiation of the members of MTC is critical in guiding treatment and public health decisions. We
carried out a study at different health units and the National Reference Laboratory in Rwanda identify
Mycobacterium tuberculosis complex species prevalent in TB patients in Rwanda. We further characterized the
isolates using spoligotyping in order to gain an insight into the strain diversity of drug resistant and susceptible
isolates of M. tuberculosis in this setting.
Methods: A total of 151 isolates from culture positive sputum samples were harvested, heat killed at 80°C for two
hours, and then shipped to Makerere University College of Health Sciences, Uganda, for speciation and typing.
Species identification was achieved by regions of difference (RD) analysis, while Spoligotyping was done to identify
strain types.
Results: Region of difference analysis identified all the 151 isolates as M. tuberculosis. Spoligotyping revealed
predominance of the T2 family (58.3%, 88/151), with SIT 52 being the most prevalent strain (31.8%, 48/151). Among
the 151 isolates, 64 (42.4%) were multidrug resistant (MDR) with 3 cases on mono-resistance. Of 94 retreatment
cases, 48 (51.1%) were MDR and of 46 newly presenting cases 14 (30.4%) were MDR. There was a significant
difference (p=0.01) in anti-TB drug resistance between new and retreatment cases in the sample. However, there
was no significant relationship between HIV serostatus and the two major strain types SIT 52 (p =0.15and SIT 152
(p = 0.41).
Conclusion: Mycobacterium tuberculosis is the most prevalent species of Mycobacterium tuberculosis complex in
Rwanda, and SIT 52 (T2) the predominant strain. There is significantly more MDR in the retreatment cases but no
significant difference was observed by HIV status in relation to any spoligotypes.Background
Together with other highly related bacteria, Mycobacter-
ium tuberculosis, the major causative agent of tuberculosis
(TB), forms a complex, the Mycobacterium tuberculosis
complex (MTC), a single species as defined by DNA/DNA
hybridization studies [1]. Other major members of the
complex include M. bovis, which is mainly responsible for
bovine TB, and M. africanum, the main causative
agent of human TB in West Africa [2,3]. World over,
many studies have shown that the propensity of* Correspondence: basiimwe@chs.mak.ac.ug
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reproduction in any medium, provided the orspread of M. tuberculosis is dependent on strains types,
and that these strains will not only be predominate in dif-
ferent settings but are also host specific [3-7]. DNA finger-
printing techniques in M. tuberculosis have made strain
typing for epidemiology possible, thus it is now practical
to predict transmission rates as well as identify and track
strains associated with outbreaks [8], severe disease [9-11],
and drug resistance [12].
In Rwanda, TB is one of the leading causes of mortality.
Recent (2010) WHO data show a burden of 106 per
100,000 population [13]. Currently, the only data available
on MTC in Rwanda focuses on drug resistance studies
[14-16], and less is known about the prevalent species
and strains, and how these relate with host demographicLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Gafirita et al. BMC Clinical Pathology 2012, 12:20 Page 2 of 7
http://www.biomedcentral.com/1472-6890/12/20characteristics as well as drug resistance of the strains.
Local studies on circulating MTC strains are important
for comparison with the global M. tuberculosis popula-
tion archived in various databases. Such knowledge
enables a better understand the global traffic of common
M. tuberculosis clades.
In the current study, genomic deletions also called
regions of difference (RDs) were used to determine the
predominant species of the MTC in TB patients in
Rwanda. We analyzed samples brought in at the national
tuberculosis reference laboratory (NRL) (located in
Kigali) between March and September 2009. According
to the National TB algorithm, NRL receives samples
from all parts of the country, mainly: new cases with
contact of known MDR patients; cases that had been on
treatment for three months and remained sputum smear
positive; and retreatment cases. Furthermore, we charac-
terized our strain collection using spoligotyping, a robust
and easy to perform technique that has found use in
tracking TB epidemics, detecting new outbreaks, and
better defining high-risk populations [17], so as to deter-
mine the genetic diversity of the strains from this locale.
Following previous reports elsewhere of significant
numbers of TB cases also co-infected with HIV [6,18],
we investigated associations between the predominant
spoligotypes and HIV sero-status of the patients as




This study was approved by the Institutional Research
and Ethics Committee of Kigali Health Institute, and
Rwanda National Ethics Committee. Informed consent to
participate in the study as well as permission to use iso-
lates from samples provided were obtained from all en-
rolled participants. A materials transfer agreement was
signed between the National Reference Laboratory (NRL)
in Kigali, and the Department of Medical Microbiology at
Makerere University College of Health Sciences, Uganda.
Study setting
Rwanda has a population of about 320 persons per
square Kilometer (2005 National Housing Census). Sam-
ples were obtained from sputum smear positive TB sus-
pects presenting to several health units in Rwanda,
between March and September 2010. These samples
were brought to NRL in Kigali. According to the Na-
tional TB algorithm, the NRL receives samples from all
health centres in the country, mainly: new cases with
contact of known MDR patients; cases that had been on
treatment for three months and remained sputum smear
positive; and retreatment cases. At the Hospitals and
Health Centres where sampling was done, suspectsprovided a spot sputum sample on the first day, and
were given another container to collect an early morning
sample, and finally another spot sample was requested
when the patient returned with the early morning sam-
ple. The sample with the highest ZN score was shipped
to the National Reference Laboratory in Kigali using
cetylpyridinium chloride-sodium chloride (CPC-NaCl)
transport medium for on ward processing and culture.
Suspects were also requested to provide 3mls of blood
for HIV testing after pre-test counselling as per routine
national policy for HIV testing in all TB patients in the
country. Rapid screening for HIV was performed at the
Hospitals and Health Centres that received the patients.
All the HIV positive patients received post-test counsel-
ling and were referred to national HIV treatment centres
for professional health care. Demographic data for each
patient sample, consisting of age, sex, and TB treatment
history were also obtained.
Sample processing
At the NRL, about 5mls of specimen were homogenized
by digestion for 1 minute at room temperature with
1 ml of N-acetyl L-cysteine (NALC, 25mg/ml) in phos-
phate buffer (pH 6.8) and vortexed with several 4 mm
glass beads for 30 seconds. A 5 ml aliquot was deconta-
minated using 1% NaOH [19] and concentrated at
4000g for 15 minutes. The sediment was then reconsti-
tuted to 2.5 mls, using phosphate buffer pH 6.8, to
make the inoculum for smears and cultures. Colonies
were harvested in 400μl of sterile Tris-EDTA (TE) buf-
fer, heat inactivated at 80°C for two hours and then
shipped to the Department of Medical Microbiology at
the College of Health Sciences, Makerere University, for
identification and typing.
Culture and drug susceptibility testing
Sediments were cultured on Lowenstein-Jensen medium
(L-J), incubated at 37°C and read weekly for growth for a
maximal duration of 10 weeks. Positive cultures were
subjected to Ziehl-Neelsen (ZN) staining for confirm-
ation of mycobacterial growth, and isolates were later
confirmed as MTC at the molecular level by a previously
described PCR typing panel [4]. Drug Susceptibility
Testing (DST) was performed by the indirect proportion
method on L-J media at the following drug concentra-
tions: rifampicin, 40μg/ml and isoniazid, 0.2μg/ml as
recommended elsewhere [20]. For all test panels, drug
susceptible strain (H37Rv) and specific drug resistant
strains (TMC 303 for isoniazid and TMC 331 for rifam-
picin) internal controls were included.
DNA extraction
Cultures with ample growth were harvested, isolates heat
killed for 2 hours and DNA extracted by the phenol-
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cultures that did not have ample harvests, heat killed iso-
lates were used directly for PCR in subsequent analyses.
RD analyses and spoligotyping
All the target genomic loci were previously well charac-
terized [22,23]. Strains were analyzed for presence of the
MTC specific 16S rRNA gene, and then RD9 (deleted in
M. africanum but present in M. tuberculosis), as well as
TbD1 (a M. tuberculosis specific deletion that is intact in
M. africanum) using previously described PCR methods
which detail primer sequences and amplification condi-
tions [4,24]. Standard spoligotyping [25] was performed
using a commercially available kit (Isogen Bioscience BV,
Maarssen, The Netherlands) following manufacturer’s
instructions.
Data analysis
Spoligotypes were analyzed by the BioNumerics soft-
ware, version 5.0 (Applied Maths, Kortrijk, Belgium) as
character types. Binary outcomes were fed into the inter-
national spoligotyping database of the Pasteur Institute
of Guadeloupe [17], which provides information on the
spoligotype international type (SIT) distributions of M.
tuberculosis spoligotypes worldwide. Statistical associa-
tions between strain types, drug susceptibility and HIV
sero-status were generated by Stata 10 using the Pear-
son’s chi-square test, and a P value of <0.05 was consid-
ered evidence of a significant difference.Figure 1 Spoligotype patterns of non-clustered M. tuberculosis strains
represent positive hybridization while empty boxes represent absence of sp
SpolDB4.0; HIV, sero-status of the patients; INH, resistance to isonaizid; RIF,Results
Study population
Samples from 153 patients were brought to the NRL
between March and September 2009 for culture, with 39
of the patients providing more than one sample for in-
ternal control, but these duplicate samples were not con-
sidered in the final statistical analysis. Furthermore, two
isolates did not amplify for the 16srRNA locus even on
repeat analysis and were thus considered atypical myco-
bacteria and excluded from further analysis. Therefore,
only isolates from 151 patients were assayed in this study.
Ninety of the 151 (59.6%) of the isolates were from male
patients. The sample median age was 36 (Interquartile
range [IQR] 28, 48). Stratification according to age
showed that 70 (49.6%) of the patients were between 18
and 35 years old (youths) while 71 (50.4%) were over
35 years of age.
Species identification
From the resulting PCR patterns for the three targeted
RD loci, all the 151 isolates were identified as M. tuber-
culosis (all deleted at the TbD1 locus), with consistent
amplification for RD9, a region that is invariably deleted
from all M. africanum → M. bovis lineage strains as pre-
viously shown elsewhere [22].
Spoligotypes
To determine the strain lineages present in the sample,
the 151 isolates were spoligotyped and binary outcomesin the study (N=36). SIT, spoligotype international type; filled boxes
acers; label defines the lineage/sub lineage; NA, not available in
resistance to rifampicin; S, sensitive; R, resistant; ND, not determined.
Figure 2 Spoligotype patterns of 115 clustered M. tuberculosis strains in the study. N, number of isolates per cluster; SIT, spoligotype
international type; filled boxes represent positive hybridization while empty boxes represent absence of spacers; label defines the
lineage/sub lineage; NA, not available in SpolDB4.0.
Gafirita et al. BMC Clinical Pathology 2012, 12:20 Page 4 of 7
http://www.biomedcentral.com/1472-6890/12/20compared with those existing in SpolDB4 so as to assign
spoligotype international type (SIT) designations. A total
of 115 isolates (76.2% of the sample) were grouped into
17 clusters (2 to 48 isolates per cluster), while the
remaining 36 (23.8%) of the strains did not cluster. Of
these 36 strains that did not cluster, 27 did not exist in
the SpolDB4.0 data base, hence represented the true
orphans in the study sample. The remaining nine of the
un clustered isolates were all present in SpolDB4 with
labels SIT 73 (T2-T3), SIT 853 (T2), SIT 1208 (H1), SIT
4 (LAM 3/S Convergent), SIT 21 (CAS_KILI), SIT 7
(T1), SIT 60 (LAM 4), SIT 815 (LAM11_ZWE) and SIT
954 (CAS_DELHI). The associated drug susceptibility
patterns for the un clustered isolates as well as HIV
sero-status of the corresponding patients for each isolate
are indicated in Figure 1.
Among the 17 clusters, only two included more than
ten isolates each and were defined as major spoligotypes,
while minor spoligotypes, in this study, were defined as
SITs that contained two to eight isolates per cluster. The
two major shared spoligotypes in our sample were SIT
52 (T2) with 48/151 (31.8%) and SIT 125 (T2) with 12/
151 (7.9%) of the isolates. Other significant clustered
spoligotypes in the sample were SIT 420 (T2) and SIT
135 (T2-Uganda) with eight strains each (Figure 2). Fur-
thermore seven clusters, ranging from two to six strains
per cluster, formed a total of 20 strains and were not yet
defined in SpolDB4.0. Among all the clustered strains,
83 of 115 (72%) were identified in SpolDB4 as T2, while
a further 15 strains that were not identified in SpolDB4
also lacked hybridization to either spacer 40 or both 40
and 43, characteristic of the T2 Euro-American lineage
of strains previously erroneously identified in Uganda asM. africanum genotypes Uganda II and I respectively
[26] but later termed M. tuberculosis Uganda genotype
strains [4].
Drug susceptibility patterns
Susceptibility testing results for the two key anti-
tuberculosis drugs (isoniazid and rifampicin) showed
that 67 isolates were susceptible to both drugs, three iso-
lates were monoresistant (two to rifampicin and one to
isonaizid), resistance to isoniazid was 65/151 (43%), and
that to rifampicin was 66/151 (43.7%), while 17 cases did
not have interpretable susceptibility results. Sixty four of
the 65 isonaizid resistant strains were also rifampicin re-
sistant hence MDR. Of the 151 patients in the study, 94
were retreatment cases, of the 46 new patients, 3 new
cases were MDR know contact patients whereas 43 new
patients were on treatment for three months and
remained microscope smear positive, while treatment
history for 11 patients could not be established. Among
the retreatment cases, 48/94 (51.1%) were MDR, while
13/46 (28.3%) of the new cases were MDR (p = 0.01). A
summary of patient demographic characteristics and
associated drug susceptibility pattern is shown in
Table 1.
Analysis of drug resistance in the major clusters
revealed that SIT 52 (T2) with 48 strains had 34/65
(52.3%) of the total isoniazid resistant strains in the sam-
ple. Furthermore, this strain type had 35/66 (53%) of the
rifampicin resistant strains and 34/64 (51.3%) of the
MDR isolates. SIT 125 (T2), on the other hand, had
eight of its12 strains resistant to both rifampicin and
isoniazid, hence MDR. Categorization of the patients
into retreatment and new cases within the two major
Table 1 Patient demographic characteristics and associated drug susceptibility pattern
Demographic characteristics Total Sensitivea Resistant
INHb RIFc MDRd
Number of strains 151 67 (44.4%) 1 (0.7%) 2 (1.3%) 64 (42.4%)
Sex Male 95 47 (49.5%) 1 (1.1%) 1 (1.1%) 34 (35.8%)
Female 56 20 (35.7%) 0 1 (1.8%) 30 (53.6%)
Treatmenthistory New cases 46 28 (60.9%) 0 0 12 (26.1%)
Retreatment 94 39 (41.5%) 1 (1.1%) 2 (2.2%) 48 (51.1%)
Unknown 11 2 (18.2%) 0 0 0
HIV status Positive 69 34 (49.3%) 0 2 (2.9%) 30 (43.5%)
Negative 76 35 (46.1%) 1 (1.3%) 0 32 (42.1%)
unknown 6 0 0 0 0
aSensitive indicates isolates susceptible to both isoniazid and rifampicin; bResistance to isonaizid only, cresistance to rifampicin only, dresistance to both isonaizid
and rifampicin. Seventeen isolates did not have complete susceptibility testing results and were excluded from the table.
Gafirita et al. BMC Clinical Pathology 2012, 12:20 Page 5 of 7
http://www.biomedcentral.com/1472-6890/12/20spoligotypes revealed that 35/48 strains in SIT 52 were
retreatment cases while 11 of the 12 cases in SIT 125
were retreatment. There were no significant statistical
associations between genotypes and drug resistance.
The relationship between the different spoligotypes in
the non clustered strains and resistance to rifampicin
and isoniazid is summarized in Figure 1.
HIV sero-status and associated spoligotypes
In the sample analyzed, 69 patients (45.7%) were HIV
sero-positive, 76 (50.3%) sero-negative, while 6 (4%) did
not have test results hence their status unknown. Of the
69 sero-positive cases, 42 (60.9%) were TB retreatment
cases while 52/76 (26.3%) of the sero-negative cases were
retreatment. An analysis of the drug susceptibility pat-
tern of isolates from the 69 HIV sero-positive individuals
showed that 31 had strains resistant to isoniazid, 32 to
rifampicin while 30 (43.5%) were MDR isolates. Ana-
lysis of the two major spoligotypes above (SIT 52 and
SIT 152) vs. HIV sero-status of patients showed that
19 of the 48 SIT 52 strains (39.6%) were from HIV
positive patients while 26/48 (54.2%) strains were from
HIV negative patients (p =0.15). Likewise 7 of the 12 SIT
152 strains (58.3%) were isolated from HIV positive
patients while 5/12 (41.7%) were from HIV negative
patients (p = 0.41). There was no statistical relationship
between HIV sero-status of the patients and any particu-
lar spoligotypes pattern. The sero-status of the patients
carrying un clustered strains in the study is shown in
Figure 1.
Discussion
This, to the best of our knowledge, is the first report
describing the species and strain diversity of M. tuber-
culosis complex isolates from TB patients in Rwanda.
Characterization of prevailing M. tuberculosis strains
focusing on different geographical levels is important
for locating the origin, evolution and spread dynamicsof particular M. tuberculosis clones, which is often diffi-
cult to be identified by traditional epidemiological inves-
tigations. In low-resource, high-disease burden settings,
it is critical to identify circulating strains in order to
understand the dynamics of spread of the causative
agent. In Rwanda, there is no data about the species and
strains of M. tuberculosis circulating in the country. This
report, therefore, will provide baseline data for future
country-wide molecular epidemiological studies to
understand transmission dynamics of TB.
Regions of Difference (RD) analysis using 16S-rRNA,
RD9 and TbD1 loci showed that all the strains investi-
gated were characterized by presence of both 16S-rRNA
and RD9 loci, and deletion in the TbD1 regions, a pat-
tern confirming that they all were M. tuberculosis strict
sense. Most studies in the East African region have
reported predominance of M. tuberculosis [4,26,27],
while most M. africanum strains isolated to date are
from West Africa [2,7,28,29].
A majority (68.2%) of the spoligotypes obtained in this
study belong to previously identified shared spoligotype
international types (SITs). A significant proportion of
the total isolates (48/151, 31.8%) belonged to SIT 52,
while only 8/151 (5.3%) were SIT 135, a strain type com-
monly seen in Uganda. SIT 52 was found to be 7.6%
(26/344) of isolates in a study in Central Uganda [18]
and 4.8% (6/125) of isolates from South Western Uganda
[30], while not a single strain of this type was seen in a
collection of 130 isolates from Northern Tanzania [31].
Generally, this genotype together with the related SIT
135 and SIT 128 are known to be the commonest
strain types causing TB in Central African human host
populations [4].
The 151 isolates in the study show 53 different spoli-
gopatterns, displaying a wide diversity of the spoligo-
types in this collection. It is known that the structure of
the TB populations is determined by geography, demog-
raphy, and human migration. The large diversity of
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increased transborder human movement in this region
due to a large influx of former refugees from different
neighboring countries in the last 15 years. Additionally,
true orphan spoligotypes accounted for only 17% of all
the spoligotypes in this study, this low percentage fur-
ther supporting the hypothesis of increased recent
human traffic in this setting, since countries with a his-
tory of isolation have been shown to have a large num-
ber of new spoligotypes, which is not the case in this
scenario [32].
Spoligotyping identified T2 to be the most predomin-
ant family of strains in Rwanda, accounting for up to
55.0% (83/151) of the total sample (Figures 1 and 2).
Results from a previous molecular study of recurrent TB
in Rwanda by spoligotyping and mycobacterial inter-
spersed repetitive unit variable number of tandem repeat
(MIRU-VNTR) typing did not show species and strain
types in the collection [16] hence we cannot compare the
two studies. Findings from the current study, however,
are in agreement with the previous data from Uganda, in
which two studies showed predominance of T2 family,
the first having been conducted at the National referral
hospital, Kampala, in which 67% of the isolates were T2
[33] and the second a systematic community based study
in Rubaga, one of the divisions of Kampala, which
reported 70% isolates being of the T2 family [18]. This re-
sult is in further agreement with those elsewhere report-
ing predominance of single genotypes in the respective
populations across Africa [2,6,7,28,34]. Collectively, these
results depict a tendency for local genotypes that are well
established to form a larger proportion of circulating
strains compared to others as previously postulated
[3,35]. Since our sample collection may not reflect a na-
tional picture, a future national survey could genotype all
isolates so as to give a clear situation of strain types as
well as transmission pattern in this locale.
In Rwanda, the most recent national anti-tuberculosis
drug resistance survey (2002–2005) on 616 new cases
[14] showed that 6.2% of the isolates were resistant to
isoniazid, 3.9% to rifampicin and 3.9% were multi-drug
resistant. In neighboring Uganda, a much earlier na-
tional survey (1996–1997) showed that of 586 patients,
resistance to isoniazid was 6.7 %, that to rifampicin was
0.8% while MDR was 0.5% [36]. The current study tested
46 new TB case, 94 retreatment cases and 11 cases with
no known history. Overall MDR was 42.4%, a very high
increase, most likely attributed to the high proportion of
retreatment cases (94/115) in our study population as
opposed to new TB cases in the previous studies.
Conclusion
Mycobacterium tuberculosis is the most prevalent spe-
cies of Mycobacterium tuberculosis complex in Rwanda,and SIT 52 (T2) the predominant strain. There is signifi-
cantly more MDR in retreatment cases but no significant
difference was observed by HIV status in relation to any
spoligotypes.
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